Hepatitis B and C among healthcare workers and patient groups at increased risk of iatrogenic transmission in the European Union/European Economic Area
Tavoschi, L., Mason, L., Petriti, U., Bunge, E., Veldhuijzen, I., Duffell, E.
Vaccinations in prison settings: A systematic review to assess the situation in EU/EEA countries and in other high income countries
Madeddu, G., Vroling, H., Oordt-Speets, A., Babudieri, S., O'Moore, É., Noordegraaf, M.V., Monarca, R., Lopalco, P.L., Hedrich, D., Tavoschi, L.
Hepatitis b and c prevalence and incidence in key population groups with multiple risk factors in the EU/ EEA: A systematic review
Mason, L.M.K., Duffell, E., Veldhuijzen, I.K., Petriti, U., Bunge, E.M., Tavoschi, L.
Natural disasters and infectious disease in Europe: a literature review to identify cascading risk pathways.
Suk, J.E., Vaughan, E.C., Cook, R.G., Semenza, J.C.
Travel-associated hepatitis A in Europe, 2009 to 2015
Beauté, J., Westrell, T., Schmid, D., Müller, L., Epstein, J., Kontio, M., Couturier, E., Faber, M., Mellou, K., Borg, M.-L., Friesema, I., Vold, L., Severi, E.
ECDC Vaccine Scheduler
The Vaccine Scheduler is an interactive tool that shows vaccination schedules for individual EU/EEA countries and specific age groups. With this tool comparisons can be made for vaccination schedules between two countries or by disease for all or a selection of countries.
- Hepatitis A
- Hepatitis B
- Human papillomavirus infection
- Influenza in humans, seasonal
- Invasive Haemophilus influenzae disease
- Meningococcal disease
- Pneumococcal disease
- Prevention and control
- Rotavirus infection
- Tick-borne diseases
Hepatitis A Seroprevalence in a population of immigrants at a French vaccination centreArchived
The authors retrospectively analyzed hepatitis A virus (HAV) seroprevalence in travellers who had been born and lived at least 1 year in a developing country, wanted to travel to a hepatitis A endemic area, and consulted at the vaccination centre of the Institut Pasteur of Paris between September 1, 2008 and February 28, 2010. HAV seroprevalence was 82.4 % for a population of 646 immigrants for whom data were available